La Jolla Pharmaceutical (LJPC) stock is seeing an astronomical rise today on the heels of the news that the clinical trial for its gelectin inhibitor -- used to treat chronic kidney disease -- was a success.
The stock rose 0.24% or $0.12 reaching $50.37 ... It also reduced its holding in La Jolla Pharmaceutical Co (NASDAQ:LJPC) by 84,114 shares in the quarter, leaving it with 1.09M shares, and cut its stake in Omeros Corp …
If you want a Stock Review on DVAX, KERX, LJPC, or MBRX then come over to http://dailystocktracker.com/register/ …
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,123,456 and 18,261,557 shares issued and …
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,123,456 and 18,261,557 shares issued and …
ABC61mon
La Jolla Pharmaceutical Co. (NASDAQ: LJPC) has seen its shares jump on this wave with an ... in a 52-week trading range of $6.17 to $24.89. The stock has a consensus analyst price target of $36.20.
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,123,456 and 18,261,557 shares issued and …
La Jolla Pharmaceutical Company (NASDAQ:LJPC) yearly performance is 45.48%. The current share price …
net 2 1 1 Preferred stock dividends - (562 ) (562 ) Net loss attributable to common shareholders $ (4,284 ) $ (3,724 ) $ 560 Research and Development Expense Our research and development efforts have been focused on the development of …
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,123,456 and 18,261,557 shares issued and …